• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
  • New
Rheumatic Immune-Related Adverse Events, An Issue of Rheumatic Disease Clinics of North America

Rheumatic Immune-Related Adverse Events, An Issue of Rheumatic Disease Clinics of North America

9780443294006
PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 14 DAYS
569.47 zł
484.05 zł Save 85.42 zł Tax included
Lowest price within 30 days before promotion: 484.05 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DHL, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Related Adverse Events. Immune checkpoint inhibitors sometimes cause rheumatic-disease-like symptoms, or rheumatic immune-related adverse events (irAEs). In this issue, top experts discuss the utility of laboratory investigations for rheumatic irAEs; the future of biomarkers in rheumatic irAEs; integrating rheumatic irAE research and care into an oncological milieu; patient voices in rheumatic irAE care and research; polymyalgia rheumatica irAEs; inflammatory arthritis irAEs:: current approaches to management; and more.
Product Details
Elsevier
100414
9780443294006
9780443294006

Data sheet

Publication date
2025
Issue number
1
Cover
hard cover
Pages count
240
Dimensions (mm)
152 x 229
Weight (g)
510
  • Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression
    Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
    The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events
    The Current and Future of Biomarkers of Immune Related Adverse Events
    Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care
    Patient Voices in Rheumatic Immune-related Adverse Events
    Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
    Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management
    Immune Checkpoint Inhibitor-induced Myositis
    Immune Checkpoint Inhibitor-induced Sicca Syndrome
    De novo Connective Tissue Disorders as Immune-related Adverse Events
    Imaging in Rheumatic Immune-related Adverse Events
    The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review
    Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease[1]Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy
Comments (0)